# Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease

> **NCT03283059** · PHASE3 · UNKNOWN · sponsor: **Shanghai Mental Health Center** · enrollment: 600 (estimated)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Octohydroaminoacridine Succinate
- **DRUG:** Aricept
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03283059
- **Lead sponsor:** Shanghai Mental Health Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-08-16
- **Primary completion:** 2020-09-16
- **Final completion:** 2021-02-16
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2019-10-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03283059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03283059, "Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03283059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*